The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.
Advanced Solid Tumors Cancer, MSI-H Cancer
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
-
USC San Diego Health, La Jolla, California, United States, 92093
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90089
University of Chicago Medicine, Chicago, Illinois, United States, 60637
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States, 40202
Cayuga Cancer Center, Ithaca, New York, United States, 14850
Taylor Cancer Research Center, Maumee, Ohio, United States, 43537
Brown University Health, Providence, Rhode Island, United States, 02901
Prisma Health Cancer Institute - Multidisciplinary Center, Greenville, South Carolina, United States, 29605
Tennessee Oncology, Nashville, Tennessee, United States, 37205
University of Virginia Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States, 22908
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 99 Years
ALL
No
Nimbus Wadjet, Inc.,
Anita Scheuber, MD, PhD, STUDY_DIRECTOR, Nimbus Therapeutics, Inc.
2031-12